Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Payables (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Payables for 6 consecutive years, with $851160.0 as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 63.85% to $851160.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $851160.0, a 63.85% decrease, with the full-year FY2024 number at $1.7 million, down 40.56% from a year prior.
  • Payables was $851160.0 for Q3 2025 at Ensysce Biosciences, down from $1.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $13.0 million in Q4 2021 to a low of $319180.0 in Q1 2021.
  • A 5-year average of $3.0 million and a median of $1.6 million in 2023 define the central range for Payables.
  • Biggest YoY gain for Payables was 2103.46% in 2021; the steepest drop was 92.14% in 2021.
  • Ensysce Biosciences' Payables stood at $13.0 million in 2021, then crashed by 43.67% to $7.4 million in 2022, then crashed by 62.03% to $2.8 million in 2023, then tumbled by 40.56% to $1.7 million in 2024, then tumbled by 48.69% to $851160.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Payables are $851160.0 (Q3 2025), $1.5 million (Q2 2025), and $872678.0 (Q1 2025).